CIR:LSE-Circassia Group Plc (GBX)

COMMON STOCK | Biotechnology | LSE

Last Closing Price

GBX 25.38

Change

0.00 (0.00)%

Market Cap

GBX 0.10B

Volume

0.09M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Circassia Group Plc, a specialty pharmaceutical company, focuses on the development and commercialization of respiratory products. It operates through three segments: NIOX, Chronic Obstructive Pulmonary Disease (COPD), and LungFit. The company markets NIOX and NIOX VERO for use in asthma diagnosis and management; Tudorza for the treatment of COPD; and Duaklir, a fixed-dose combination of the long-acting muscarinic antagonist aclidinium bromide and long-acting beta agonist formoterol fumarate, which is administered twice-daily through the breath actuated Pressair inhaler for the maintenance treatment of COPD. It is also developing LungFit, a portable ventilator-compatible system that utilizes an electric voltage to produce precise quantities of nitric oxide from the nitrogen and oxygen in air. The company markets its products directly to specialists in the United States, the United Kingdom, China, Italy, and Germany, as well as through a network of partners internationally. Circassia Group Plc has a collaboration agreement with AstraZeneca to promote Tudorza and Duaklir for COPD treatment; and the United States and Chinese commercial rights to LungFit. The company was formerly known as Circassia Pharmaceuticals plc and changed its name to Circassia Group Plc in May 2020. Circassia Group Plc was founded in 2006 and is headquartered in Oxford, the United Kingdom. Address: Northbrook House, Oxford, United Kingdom, OX4 4GA

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-06 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ABC:LSE Abcam plc

N/A

GBX3.47B 255.33 95.60
GNS:LSE Genus plc

N/A

GBX3.24B 67.36 38.81
HCM:LSE Hutchison China MediTech Limit..

N/A

GBX3.10B 17.41 N/A
PRTC:LSE PureTech Health plc

N/A

GBX1.19B 2.61 1.59
OXB:LSE Oxford Biomedica plc

N/A

GBX0.82B N/A 615.00
ERGO:LSE Ergomed plc

N/A

GBX0.58B 95.20 49.78
SLN:LSE Silence Therapeutics plc

N/A

GBX0.51B N/A N/A
AVCT:LSE Avacta Group Plc

N/A

GBX0.50B N/A N/A
SNG:LSE Synairgen plc

N/A

GBX0.33B N/A N/A
ARIX:LSE Arix Bioscience plc

N/A

GBX0.25B 13.11 N/A

ETFs Containing CIR

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -10.02% 20% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -10.02% 20% F 9% F
Trailing 12 Months  
Capital Gain 25.93% 38% F 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.93% 38% F 68% D+
Trailing 5 Years  
Capital Gain -90.67% 9% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -90.67% 9% F 2% F
Average Annual (5 Year Horizon)  
Capital Gain -21.32% 10% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -21.32% 10% F 5% F
Risk Return Profile  
Volatility (Standard Deviation) 40.48% 67% D+ 26% F
Risk Adjusted Return -52.67% 12% F 16% F
Market Capitalization 0.10B 55% F 43% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.35 93% A 53% F
Price / Cash Flow Ratio -4.02 27% F 69% D+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -56.35% 46% F 12% F
Return on Invested Capital -20.09% 64% D 14% F
Return on Assets -12.43% 66% D 14% F
Debt to Equity Ratio 129.60% 33% F 14% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.88 17% F 6% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.